Profound Medical Corp
🇺🇸XNAS.PROFUnited StatesHealthcare
Price$5.75+0.12 (+2.13%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 8
- Medium: 1
- Low: 0
Cash conversion cycle: a sudden spike above its trailing quarter average
Days inventory outstanding: a sudden spike above its trailing quarter average
Free cash flow to debt: a sudden drop below its trailing quarter average
Net profit margin: a sudden drop below its trailing quarter average
Operating profit margin: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Medical Devices
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- CA74319B5027
- CUSIP
- 74319B502
Company
- Employees
- 142
- Headquarters
- Mississauga, United States
Market
- Shares outstanding
- 36.5M
- Market cap
- $199.53M
Key dates
- Next earnings
- Nov 12, 2026
Highlights
- Market cap
- $199.53M
- EPS LTM
- -$1.36
- P/E LTM
- -6.06
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $11.84M+50.25%up year on year
- Net income
- -$40.73M-47.62%down year on year
- Gross margin
- 69.43%+13.37%up year on year
- Free cash flow
- -$34.03M-49.24%down year on year
Latest news
Business summary
Profound Medical Corp is a company in the healthcare sector, listed on Nasdaq (United States) under the ticker PROF. Its market capitalisation is $199.53M, from 36.5M shares outstanding, as of . Across the 250 trading sessions to the shares traded between $4.81 and $8.93, and the last close of $5.75 sits 23% of the way up that range. The company is headquartered in Mississauga, United States, and employs about 142 people. This is the Nasdaq listing of Profound Medical Corp; its primary listing is PRN on Toronto Stock Exchange.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.